您现在的位置: 首页> 研究主题> 放射疗法,调强

放射疗法,调强

放射疗法,调强的相关文献在2005年到2021年内共计62篇,主要集中在肿瘤学、特种医学 等领域,其中期刊论文62篇、专利文献26720篇;相关期刊4种,包括中国老年学杂志、中华放射肿瘤学杂志、新疆医科大学学报等; 放射疗法,调强的相关文献由312位作者贡献,包括韩非、卢泰祥、李晔雄等。

放射疗法,调强—发文量

期刊论文>

论文:62 占比:0.23%

专利文献>

论文:26720 占比:99.77%

总计:26782篇

放射疗法,调强—发文趋势图

放射疗法,调强

-研究学者

  • 韩非
  • 卢泰祥
  • 李晔雄
  • 苏胜发
  • 赵充
  • 陈春燕
  • 王淑莲
  • 王维虎
  • 肖巍魏
  • 金晶
  • 期刊论文
  • 专利文献

搜索

排序:

学科

年份

    • 孙学明; 卢晓旭; 黄蓉; 吴慧
    • 摘要: 目的 评价不同诱导化疗疗效对非高发区局部晚期鼻咽癌患者调强放疗同期化疗疗效及预后影响因素.方法 回顾分析2012-2017年间初治的210例Ⅲ-ⅣB期(排除T3-4N0M0期)鼻咽癌患者资料,根据不同诱导化疗疗效分为有效组(完全缓解14例+部分缓解165例)和无效组(稳定31例+0例进展).Kaplan-Meier法生存分析,Cox模型多因素分析.结果 与无效组相比,有效组3年总生存率较高(89.2%:74.2%,P=0.005),3年无复发生存率较高(93.0%:81.9%,P=0.010),3年无进展生存率较高(80.2%:58.1%,P=0.005),但无远处转移生存相近(84.1%:69.7%,P=0.070).多因素分析显示诱导化疗疗效是影响总生存、无复发生存、无进展生存的独立预后因素.结论 诱导化疗疗效可预测非高发区局部晚期鼻咽癌患者的预后,诱导化疗后无效患者预后更差,或许需要对这些患者采用更高强度的治疗方案以及更密切的随访.
    • 李青松; 陈霞霞; 卢冰; 欧阳伟炜; 苏胜发; 马筑; 耿一超; 杨文刚; 胡银祥; 栗蕙芹; 李晓阳
    • 摘要: 目的 回顾分析伴恶性胸腔积液(MPE)的非小细胞肺癌(NSCLC)原发灶放疗相关因素对生存影响.方法 2007-2019年间经病理学证实、初治的伴MPE的NSCLC共256例,其中117例纳入分析.按放疗剂量<63 Gy与≥63 Gy分为2个组,采用倾向性评分匹配法均衡组间混杂因素(卡钳值= 0.1).Kaplan-Meier法计算生存并log-rank单因素分析,Cox模型多因素分析放疗相关因素对总生存(OS)影响.结果 原发灶放疗可延长OS(P<0.001),且随剂量36.0~44.1 Gy、45.0~62.1 Gy、63.0~71.1 Gy提高OS延长(P<0.001),中位生存期分别为5、13、18个月.匹配前单因素分析显示原发灶剂量≥63 Gy、大体肿瘤体积<157.7 cm3、引流区淋巴结转移≤5站的OS延长(均P<0.05),T4N3期较其他期患者OS降低(P= 0.018);匹配后单因素分析显示原发灶剂量≥63 Gy的OS仍延长(P=0.013),≤5站引流区淋巴结转移OS呈延长趋势(P=0.098).匹配前多因素分析显示原发灶放疗剂量≥63 Gy是延长生存的独立预后因素(HR=0.566,95%CI为0.368~0.871,P=0.010),GTV<157.7 cm3有延长OS趋势(HR=0.679,95%CI为0.450~1.024,P=0.065);匹配后多因素分析显示原发灶放疗剂量≥63 Gy仍是延长生存的独立预后因素(HR = 0.547,95%Cl为0.333~0.899,P=0.017).3级急性放射性食管炎和放射性肺炎分别为9.4%、5.1%,无≥4级不良反应.结论 MPE-NSCLC在胸腔积液可控的前提下,原发灶放疗剂量对延长OS可能起关键作用.
    • 喻洁; 李卿; 曾道林; 易汉杰; 刘光金; 兰琼玉
    • 摘要: 目的 探讨容积调强弧形治疗(VMAT)和固定野动态调强放疗(IMRT)在左侧乳腺癌改良根治术后需辅助放疗并内乳淋巴结照射患者的剂量学差异.方法 对20例左侧乳腺癌患者制定VMAT和IMRT两种放疗计划.通过剂量体积直方图计算靶区和危及器官剂量学参数.对分类变量行x2或Fisher's精确概率法检验,连续变量根据正态性采用配对t检验或秩和检验.结果 IMRT靶区均匀性指数比VMAT高(P<0.05).VMAT治疗时间较IMRT更短(P<0.01).VMAT患侧肺V20Gy、V30Gy优于IMRT (P<0.05).VMAT在冠脉左前降支Dmean、Dmax和心脏V30Gy、V40Gy、Dmean、Dmax优于IMRT(P<0.01).食管DmeanVMAT优于IMRT (P<0.05),但健侧肺V5Gy、V10Gy和食管DmaxIMRT优于VMAT(P<0.05).结论 VMAT可以显著减少心脏、健侧肺、脊髓、食管照射剂量,缩短治疗时间.对于左侧乳腺癌根治术后需辅助放疗并照射内乳淋巴结的患者,VMAT技术比IMRT技术可以更好保护正常组织.
    • 徐敏; 王素贞; 王玮; 邵倩; 张英杰; 李奉祥; 李建彬
    • 摘要: 目的 比较早期乳腺癌保乳术后瘤床同步补量IMRT (SIB-IMRT)与瘤床后程补量IMRT (LB-IMRT)在放射损伤及疗效方面的差异性.方法 选择2002-2012年间在山东省肿瘤医院行早期乳腺癌保乳术后IMRT的患者353例,其中218例接受SIB-IMRT,135例接受LB-IMRT.SIB-IMRT组处方剂量为瘤床(PTVt)2.15~2.3 Gy 27~28次和乳腺(PTVb) 1.8~ 1.9 Gy,27~28次;LB-IMRT组处方剂量PTVb为2.0 Gy 25次,后续PTV1补量2.0Gy,5~8次.结果 中位随访期92个月.SIB-IMRT组与LB-IMRT组的美容效果优、良、一般、差者分别为10.1%、85.8%、3.7%、0.5%和12.6%、80.7%、5.2%、0.7%(P=0.731).SIB-IMRT组和LB-IMRT组5年局部区域复发率(LRR)分别为3.21%和5.93%,10年LRR分别为4.13%和6.67% (P=0.209、0.280).SIB-IMRT组和LB-IMRT组3、5、8、10年总生存率分别为97.7%、96.3%、94.9%、93.6%和97.8%、95.2%、92.0%、90.3%(P=0.288).SIB-IMRT组和LB-IMRT组3、5、8、10年无瘤生存率分别为95.4%、91.8%、89.9%、89.0%和93.8%、87.7%、84.1%、82.1%(P=0.160).结论 保乳术后瘤床SIB-IMRT与LB-IMRT在美容效果、局控率、生存率等方面均相近,是安全可行的治疗方法.
    • 顾文栋; 李齐林; 田野; 莫俊聪; 裴红蕾
    • 摘要: Objective To investigate the effects of hippocampal⁃sparing intensity⁃modulated radiotherapy ( IMRT) on dose distribution of target volume and organs at risk ( OARs) in locally advanced nasopharyngeal carcinoma. Methods A retrospective dosimetric analysis was performed among 11 patients with locally advanced nasopharyngeal carcinoma. The MONACO v5. 10 Treatment Planning System was used to design three treatment plans:routine volumetric modulated arc therapy ( VMAT ) , hippocampal⁃sparing VMAT, and nine fixed⁃fields IMRT. The D98%, D50%, D2%, Dmean , conformity index ( CI ) , and homogeneity index (HI) of planning target volume (PTV) and PTVnx as well as dose distribution of the hippocampus and OARs were evaluated. Using single factor analysis of variance,two group comparative was LSD or paired t⁃test. Results For the above three plans,the D2% values of PTVnx were ,7 513,and 7 462 cGy,respectively (P=0. 016);the D98% values of PTV were 5837,5812,and 5914 cGy,respectively (P=0. 029);the average D2% values of PTV were 7 399,7 380,and 7 333 cGy,respectively ( P=0. 047);the HI values of PTV were 0. 239,0. 241,and 0. 220,respectively (P=0. 016);the V10 values of the brain stem were 97. 2%,88. 1%,and 90. 3%,respectively ( P=0. 001);the V20 values of the brain stem were 74. 2%, 62. 3%,and 67. 1%,respectively ( P=0. 032);the V30 values of the brain stem were 50. 9%,35. 8%,and 45. 5%, respectively ( P= 0. 020 );the V40 values of brain stem were 24. 4%, 14. 4%, and 23. 3%, respectively ( P=0. 018);the Dmean values of hippocampus were 1 518,899,and 896 cGy,respectively ( P=0. 000);the D40% values of hippocampus were 1 379,642,and 639 cGy,respectively ( P=0. 000);the V10 values of the hippocampus were 54. 1%,25. 1%,and 3. 8%,respectively ( P=0. 000);the V20 values of the hippocampus were 26. 2%, 12. 6%, and 12. 0%, respectively ( P=0. 001 ) . Conclusions Hippocampal⁃sparing VMAT and nine fixed⁃fields IMRT can significantly reduce the dose to the hippocampus without affecting dose distribution of target volume and OARs. VMAT may be superior to IMRT because VMAT can simultaneously reduce the dose to the brain stem.%目的:研究局部晚期鼻咽癌保护海马的IMRT计划对靶区及OAR剂量的影响。方法对2015年间的11例局部晚期鼻咽癌患者做回顾性剂量分析研究。 MONACO5.10TPS设计常规VMAT、保护海马VMAT和9个野IMRT计划。评价PTV及PTVnx的D98%、D50%、D2%、Dmean、CI、HI值及海马和OAR剂量。单因素方差分析,两两比较LSD法或配对t检验。结果常规VMAT、保护海马VMAT、9个野IMRT计划PTVnx的D2%分别为7542、7513、7462 cGy ( P=0.016);PTV的D98%分别为5837、5812、5914 cGy (P=0.029),D2%分别为7399、7380、7333 cGy (P=0.047),HI 分别为0.239、0.241、0.220( P=0.016);脑干 V10分别为97.2%、88.1%、90.3%( P=0.001), V20分别为74.2%、62.3%、67.1%( P=0.032),V30分别为50.9%、35.8%、45.5%( P=0.020),V40分别为24.4%、14.75424%、23.3%( P=0.018);海马Dmean分别为1518、899、896 cGy ( P=0.000),D40%分别为1379、642、639 cGy (P=0.000),V10分别为54.1%、25.1%、3.8%(P=0.000),V20分别为26.2%、12.6%、12.0%( P=0.001)。结论保护海马的VMAT和9个固定野IMRT比常规VMAT可降低海马剂量,并不影响靶区及OAR剂量分布。保护海马的VMAT计划可同时降低脑干剂量,优势更明显。
    • 任雪姣; 王澜; 韩春; 田华; 刘丽虹; 李晓宁; 高超
    • 摘要: Objective To observe the long⁃term survival and adverse reactions in patients with stage T4 N (+) Ⅲ middle and lower thoracic esophageal carcinoma undergoing intensity⁃modulated radiotherapy ( IMRT) . Methods From 2004 to 2010, 300 patients with stage T4 N (+) Ⅲ middle and lower thoracic esophageal carcinoma, consisting of 202 treated with three⁃dimensional conformal radiotherapy ( 3DCRT ) and 98 treated with IMRT, were enrolled as subjects. All patients received conventionally fractionated radiotherapy with a prescribed dose of 60 Gy. The long⁃term survival and adverse reactions were compared between patients treated with the two different radiotherapy regimens. The survival rates were calculated by the Kaplan⁃Meier method and analyzed by the log⁃rank test. Results The 5⁃and 7⁃year sample sizes were 239 and 120, respectively. The 3DCRT group had significantly lower 1⁃, 3⁃, 5⁃, and 7⁃year local control (LC) and overall survival (OS) rates than the IMRT group (64. 4% vs. 68. 3%, 40. 6% vs. 55. 3%, 38. 3% vs. 51. 9%, 34. 2% vs. 51. 9%, P=0. 048;54. 5% vs. 63. 3%, 19. 8% vs. 34. 7%, 14. 7% vs. 24. 4%, 10. 9% vs. 20. 3%, P=0. 013) . The stratified analysis showed that for patients older than 65 years, with the length of esophageal lesion>8. 0 cm before radiotherapy, the largest diameter of esophageal lesion in computed tomography image>4. 6 cm, gross tumor volume ( GTV)>60 cm3 , metastases to adjacent tissues or organs, stage N2 , and without chemotherapy, the IMRT group had a significantly higher OS rate than the 3DCRT group (P=0. 022,0. 003,0. 022,0. 034,0. 016,0. 044,0. 047). The GTV Dmin and GTVD100 were significantly higher in the IMRT group than in the 3DCRT group ( P=0. 000,0. 000) , while the Dmax of the spinal cord was significantly lower in the IMRT group than in the 3DCRT group ( P=0. 000) . Compared with the 3DCRT group, the IMRT group had a significantly higher incidence of acute radiation⁃induced esophagitis, particularly grade 1⁃2 esophagitis (P=0. 000). The mortality rate caused by local tumor was significantly higher in the 3DCRT group than in the IMRT group ( P= 0. 039 ) . Conclusions In the treatment of locally advanced middle and lower thoracic esophageal carcinoma, IMRT is safe and effective;it significantly improves the LC rate and long⁃term survival without severe toxicity to normal tissues. The results of this retrospective study need to be confirmed by prospective randomized controlled studies.%目的:观察T4 N (+)Ⅲ期食管胸中下段癌IMRT长期生存情况及不良反应。方法2004—2010年间300例T4 N (+)Ⅲ期食管中下段癌患者采用3DCRT 202例、IMRT 98例,常规分割照射剂量60 Gy。比较两种不同治疗方式的长期生存情况及不良反应。 Kaplan Meier法计算生存率并Logrank法检验。结果5、7年样本量分别为239、120例。3DCRT和IMRT组1、3、5、7年LC率分别为64.4%、40.6%、38.3%、34.2%和68.3%、55.3%、51.9%、51.9%( P=0.048),OS率分别为54.5%、19.8%、14.7%、10.9%和63.3%、34.7%、24.4%、20.3%( P=0.013)。分层分析显示年龄>65岁、放疗前食管造影长度>8.0 cm、CT最大横径>4.6 cm、GTV>60 cm3、邻近组织或器官受累、非手术N2期、未行化疗者,IMRT组OS率高于3DCRT组( P=0.022、0.003、0.022、0.034、0.016、0.044、0.047)。 IMRT组GTV Dmin、GTVD100高于3DCRT组( P=0.000、0.000),脊髓Dmax低于3DCRT组( P=0.000)。 IMRT组急性放射性食管炎发生率明显高于3DCRT组,以轻度(1—2级)食管炎为著( P=0.000)。3DCRT组死于肿瘤局部因素的比率明显高于IMRT组( P=0.039)。结论局部晚期食管胸中下段癌IMRT安全有效,LC率明显提高,正常组织保护良好,长期生存获益显著。基于回顾分析结果还有待前瞻性随机对照研究的证实。
    • 姚成云; 王丽君; 孔诚; 张兰芳; 何侠; 黄生富; 张宜勤
    • 摘要: 目的 探讨鼻咽癌IMRT发生放射性脑干损伤的发生率与照射剂量体积关系.方法 回顾分析2005-2013年单治疗组连续收治初治鼻咽癌患者258例,统计脑干单位体积剂量,分析IMRT出现放射性脑干损伤的发生率与照射剂量体积的关系.Kaplan-Meier法计算生存率,脑干放射性损伤的影响因素采用Cox模型分析.结果 2例T3期、3例T4期患者发生放射性脑干损伤.脑干放射性损伤的3、5年发生率分别为1.6%、2.4%.损伤潜伏期为9~58个月(中位数19个月).全组患者、T3期、T4期患者脑干D1%中位数分别为54.24、54.31、61.29 Gy,5例损伤患者均>60 Gy;脑干Dmax中位数分别为59.22、59.45、66.37 Gy,5例损伤患者均>63 Gy.单因素分析显示放射性脑干损伤发生与其D1%、Dmax、D0.1cm3、D0.5cm3、D1.0cm3显著相关(P=0.01、0.01、0.01、0.01、0.01).当脑干D1%≤60 Gy、Dmax≤63 Gy、D0.1cm3≤60 Gy、D05cm3≤58 Gy和D10cm3≤56 Gy时,发生放射性损伤概率可能较低(P=0.00、0.00、0.00、0.00、0.oo).结论 鼻咽癌IMRT后出现放射性脑干损伤发生率较低.严格控制脑干受量,对降低放射性脑干损伤发生、提高患者远期生活质量可能有益.%Objective To investigate the relationship between the incidence of radiation-induced brain stem injury after intensity-modulated radiotherapy (IMRT) and the radiation dose volume in patients with nasopharyngeal carcinoma.Methods A retrospective analysis was performed on the data of 258 patients newly diagnosed with nasopharyngeal carcinoma who received IMRT in our group from 2005 to 2013.The radiation dose per unit volume of brain stem was analyzed.The relationship between the incidence of brain stem injury induced by IMRT and the radiation dose volume was studied.The survival rate was calculated using the Kaplan-Meier method.The factors influencing the radiation-induced brain stem injury were analyzed using the Cox regression model.Results Two patients with stage T3 disease and three patients with T4 disease had radiation-induced brain stem injury.The 3-and 5-year injury incidence rates were 1.6% and 2.4%,respectively.The latency ranged between 9 and 58 months,with a median latency of 19 months.The median D1% and Dmax for the brain stem were 54.24 and 59.22 Gy in all patients,54.31 and 59.45 Gy in patients with stage T3 disease,and 61.29 and 66.37 Gy in patients with stage T4 disease,respectively.In the five patients with brain stem injury,the D1% and Dmax were larger than 60 and 63 Gy,respectively.The univariate analysis showed that the incidence of radiation-induced brain stem injury was correlated with D1%,Dmax,D0.1 cm3,D0.5 cm3,and D1.0 cm3 (all P=0.01).The incidence of radiation-induced brain stem injury was significantly lower in patients with D1%,Dmax,D0.1 cm3,D0.5 cm3,and D1.0 cm3 no larger than 60,63,60,58,and 56 Gy,respectively (all P =0.00).Conclusions The incidence of radiation-induced brain stem injury after IMRT is relatively low in patients with nasopharyngeal carcinoma.Strict control of the dose to the brain stem may help to reduce the incidence of brain stem injury and improve the long-term quality of life.
    • 李凯新; 辛培玲; 陈媛媛; 陈明
    • 摘要: 目的 通过前瞻性分析资料齐全的同期放化疗局部晚期鼻咽癌患者的剂量学及临床相关因素,寻找急性放射性口腔黏膜炎的预测因子.方法 对2015—2016年间连续入组的92例局部晚期鼻咽癌IMRT同步化疗患者采用RTOG评分标准进行急性放射性黏膜炎评分,定义评分≥3为重度放射性黏膜炎.获取临床资料,从IMRT计划系统获取患者的DVH剂量学参数信息.对可能预测重度黏膜炎的因素进行统计分析.结果 全组患者重度急性放射性口腔黏膜炎的发生率为21%(19/92),体重下降、口腔黏膜V30是重度黏膜炎的相关因素(P=0017、0003).ROC曲线分析显示口腔黏膜V30诊断重度放射性口腔黏膜炎的阈值为7316%(敏感性0842,特异性0671),ROC的AUC值0753(P=0001).结论 体重下降和口腔黏膜V30是重度黏膜炎的预测因素.%Objective To prospectively determine the dosimetric and clinical factors for predicting the risk of acute radiation oral mucositis ( ROM ) in patients receiving intensity?modulated radiotherapy ( IMRT) with concurrent chemotherapy for local advanced nasopharyngeal carcinoma. Methods Ninety?two patients who were treated with IMRT with concurrent chemotherapy from 2015 to 2016 for local advanced nasopharyngeal carcinoma were included in this study, and their acute ROM was scored according to the RTOG criteria. Grade≥3 ROM was used as a surrogate marker for severe mucositis, which was defined as a toxicity endpoint. The clinical data were reviewed, and the dose?volume histograms ( DVHs) of the patients were exported from the IMRT planning system. Optimal thresholds for predicting the incidence of severe ROM were evaluated by the area under the receiver operating characteristic ( ROC) curve ( AUC) . Results The incidence of severe ROM was 21%(19/92). Weight loss and V30 of the oral mucosa were determined as the independent predictors for severe ROM ( P=0017 and 0003, respectively) . The optimal cut?off point and AUC of V30 of the oral mucosa as a predictor for severe ROM were 7316%( 0842 sensitivity and 0671 specificity) and 0753( P=0001) , respectively. Conclusion Weight loss and V30 of the oral mucosa are predictors for severe ROM.
    • 涂剑楠; 佐合拉古丽·木塔力甫; 张洁; 叶伟军; 金华
    • 摘要: 目的 比较宫颈癌术后图像引导VMAT (IG-VMAT)与固定野IMRT (FF-IMRT)的剂量学差异和不良反应.方法 选取2013年间两家医院收治70例Ⅰb-Ⅱa期宫颈癌术后具有高危因素患者,均分为FF-IMRT与IGRT-VMAT组,比较两组患者靶区剂量和不良反应差异.结果 IG-VMAT组分次间x、y、z轴向摆位误差分别为(0.25±0.14)、(0.26±0.16)、(0.24±0.18) cm,分次内的分别为(0.1±0.09)、(0.12±0.09)、(0.11±0.09) cm;x、y、z轴向外扩边界分别为0.75、0.84、0.78 cm.在相同处方剂量下IG-VMAT组适形度、治疗时间、机器跳数明显优于FF-IMRT(P=0.000).IG-VMAT组膀胱、直肠和小肠Dmean、高剂量受照体积均低于FF-IMRT组(P=0.000).IG-VMAT组急慢性胃肠道、泌尿系统及血液系统不良反应发生率明显降低(P<0.05).结论 IG-VMAT不仅能在线实时调整摆位误差,且缩短治疗时间、降低OAR受量、减轻急慢性不良反应,适用于术后小肠位置下移者.%Objective To compare the dosimetry and toxicities between postoperative fixed-field intensity-modulated radiotherapy (FF-IMRT) and image-guided radiation therapy/volumetric modulated arc therapy (IGRT-VMAT) for cervical cancer.Methods A total of seventy patients with stage I b-Ⅱa postoperative cervical cancer who had high risk factors,were divided into FF-IMRT (FF-IMRT group,n =35)and IGRT-VMAT (IGRT-VMAT group,n =35),to compare the difference of target dose and adverse reaction between the two groups.Results In the IGRT-VMAT group,the interfractional setup errors in the x,y,and z axes were (0.25±0.14) cm,(0.26±0.16) cm,and (0.24±0.18) cm,respectively;the intrafractional setup errors in the x,y,and z axes were (0.1±0.09) cm,(0.12±0.09) cm,and (0.11±0.09) cm,respectively;the margins in the x,y,and z axes were 0.75 cm,0.84 cm,and 0.78 cm,respectively.Under the same dosimetric conditions,the IGRT-VMAT group was superior to the FF-IMRT group in terms of conformity index,treatment time,and number of monitor units (P=0.000).The Dmean and volume receiving high-dose irradiation for the bladder,rectum,and small intestine were significantly lower in the IGRT-VMAT group than in the FF-IMRT group (P=0.000).Compared with the FF-IMRT group,the IGRT-VMAT group had a significantly reduced incidence of acute and chronic gastrointestinal,urinary,and hematologic toxicities (P< 0.05).Conclusions IGRT-VMAT can correct setup error online,shorten the treatment time,reduce the dose to organs at risk,and alleviate acute and chronic toxicities,and is especially suitable for patients with postoperative small bowel position changes.
    • 孙学明; 陈春燕; 韩非; 卢泰祥
    • 摘要: Objective To compare the long-term efficacy between intensity-modulated radiotherapy (IMRT) alone and concurrent chemoradiotherapy (CCRT) in the treatment of stage Ⅱ nasopharyngeal carcinoma (NPC) patients.Methods The clinical data of 123 patients with stage Ⅱ NPC were retrospectively analyzed.Eighty-one patients received IMRT alone,and 42 patients received CCRT.The Kaplan-Meier method was used to calculate survival rates,and the log-rank test was used to compare the survival rates.Results The 5-year overall survival (OS),local recurrence-free survival (LRFS),distant metastasis-free survival (DMFS),and progression-free survival (PFS) rates in all patients were 96.7%,94.7%,93.1%,and 87.8%,respectively.There were no significant differences between the patients receiving IMRT alone and CCRT in 5-year OS (98.7% vs.92.9%,P=0.569),LRFS (94.8% vs.94.5%,P =0.770),DMFS (94.5% vs.90.2%,P =O.408),and PFS (90.6% vs.82.2%,P =0.340).For patients with stage T2N1 NPC,the 5-year OS,LRFS,DMFS,and PFS also showed no significant differences between those receiving IMRT alone and CCRT (P=0.929,0.967,0.917,0.492).The incidence rates of neutropenia,leukopenia,and mucositis were significantly higher in patients receiving CCRT than in those receiving IMRT alone (P=0.000,0.000,0.012,0.010),while the incidence of late toxicities was similar between the two groups of patients (P=O.823,0.622,O.113).Conclusions For stage Ⅱ NPC patients treated with IMRT,the addition of concurrent chemotherapy fails to improve the prognosis,and increases the incidence of acute toxicities.%目的 评价以IMRT为基础的不同治疗模式对Ⅱ期鼻咽癌患者预后的影响.方法 回顾分析123例Ⅱ期鼻咽癌患者的临床资料,其中单纯放疗81例,同期放化疗42例.Kaplan-Meier计算生存率并Logrank检验.结果 全组5年OS、LRFS、DMFS、PFS分别为96.7%、94.7%、93.1%、87.8%.单纯放疗组与同期放化疗组相比,5年OS (98.7%:92.9%,P=0.569)、LRFS (94.8%:94.5%,P=O.770)、DMFS (94.5%:90.2%,P=0.408)、PFS (90.6%:82.2%,P=0.340)均无明显差异.T2N1期患者两组5年各项生存率仍无明显差异(P=0.929、0.967、0.917、0.492).急性不良反应方面同期放化疗组中性粒细胞减少、白细胞减少、血红蛋白减少和放射性黏膜反应发生率明显升高(P=O.000、0.000、0.012、0.010),而两组晚期不良反应发生率相近(P=0.823、0.622、0.113).结论 对Ⅱ期患者同期化疗的加入并未改善患者预后,但急性不良反应明显增加.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号